Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
Korean J Intern Med. 2022;37(5):895-905. Published online 2022 Jul 27 DOI: https://doi.org/10.3904/kjim.2022.132
Citations to this article as recorded by 
Traditional herbal pair Portulacae Herba and Granati Pericarpium alleviates DSS-induced colitis in mice through IL-6/STAT3/SOCS3 pathway
Zhe Cheng, Yi Zhou, Xinyu Xiong, Lingli Li, Zekai Chen, Fan Wu, Ruolan Dong, Qiong Liu, Yan Zhao, Shujun Jiang, Qin Yu, Guang Chen
Phytomedicine.2024; 126: 155283. CrossRef
Natural products targeting Nrf2/ARE signaling pathway in the treatment of inflammatory bowel disease
Botong Li, Yixuan Wang, Xiaolin Jiang, Hongwei Du, Yan Shi, Minghui Xiu, Yongqi Liu, Jianzheng He
Biomedicine & Pharmacotherapy.2023; 164: 114950. CrossRef
Mesalazine-induced esophageal ulcers. a rare adverse effect
Raúl José Díaz Molina, Carlos Comesaña Castellar, Marcelo García Hernández, Carmen Garrido Durán, Marco Antonio Martínez Ortega, Daniel Ginard Vicens
Revista Española de Enfermedades Digestivas.2023;[Epub] CrossRef
Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
Catherine O’Reilly, Susan Mills, Mary C. Rea, Aonghus Lavelle, Subrata Ghosh, Colin Hill, R. Paul Ross
Microbiome Research Reports.2023;[Epub] CrossRef
Microbial Modulation in Inflammatory Bowel Diseases
Jongwook Yu, Jae Hee Cheon
Immune Network.2022;[Epub] CrossRef